Accès ouvert
2026
review
OpenAlex
Kyle Valentino, Hana Ballum, William Cheung, Christine E. Dri et autres
BACKGROUND: Approximately 80% of individuals diagnosed with major depressive disorder (MDD) report symptoms of insomnia. Glutamatergic modulators, such as ketamine, are reported to be effective for the treatment of depressive symptomatology in adults with MDD. Disrupted glutamate homeostasis is linked to poor …
ca, cn, hk
(code pays fourni par la source)
Accès ouvert
2026
editorial
OpenAlex
Kyle Valentino, Kayla M. Teopiz, Christine E. Dri, Jennifer Swainson et autres
1. Esketamine as monotherapy or adjunct to conventional antidepressants is proven efficacious in clinical trials in adults with treatment-resistant depression (TRD) and depression with high risk of...
ca
(code pays fourni par la source)
Accès ouvert
2026
review
OpenAlex
Allyssa Chan, Andy Lu, Trisha Menon, Sabrina Wong et autres
BACKGROUND: Negative symptoms in schizophrenia (SCZ) are core phenomenological characteristics known to affect health-related quality of life (HRQoL) and functioning. This systematic review aims to synthesize extant literature to evaluate/elucidate the effect of negative symptoms on HRQoL and functional outcomes in persons …
ca
(code pays fourni par la source)
Accès ouvert
2025
review
OpenAlex
Serene Lee, Liyang Yin, Kayla M. Teopiz, SL Wong et autres
Extant literature pertaining to the administration of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for Alzheimer's disease, Parkinson's disease, major depressive disorder, bipolar disorder, substance-, alcohol- and nicotine-use disorders, suggests promising efficacy beyond the current FDA-approved indications (e.g., type 2 diabetes mellitus, obesity). The …
ca, us, sg, hk
(code pays fourni par la source)